Ionis Pharmaceuticals (IONS) Cost of Revenue (2018 - 2026)

Ionis Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $2.7 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 34.02% year-over-year to $2.7 million; the TTM figure through Jun 2026 stood at $16.0 million (up 52.33% YoY), while the FY2025 annual figure was $15.9 million, up 41.85% from the prior year.
• Cost of Revenue for Q2 2026 stood at $2.7 million, down from $3.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $8.0 million in Q4 2025, with the low at $1.1 million in Q3 2024.
• The 5-year median for Cost of Revenue is $2.9 million (2026), against an average of $3.1 million.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue sank 67.79% in 2023, then jumped 118.3% in 2025.
• Ionis Pharmaceuticals' Cost of Revenue stood at $3.7 million in 2022, then dropped by 16.93% to $3.1 million in 2023, then gained by 25.08% to $3.8 million in 2024, then jumped by 107.75% to $8.0 million in 2025, then sank by 65.58% to $2.7 million in 2026.
• Business Quant data shows IONS's Cost of Revenue at $2.7 million in Q2 2026, $3.0 million in Q1 2026, and $8.0 million in Q4 2025.